CN105263941A - 2-{[(2r,3s,5r)-5-(4-氨基-2-氧代-2h-嘧啶-1-基)-3-羟基-四氢-呋喃-2-基甲氧基]-苯氧基-磷酰基氨基}-丙酸烷基酯类、hcv rna-聚合酶ns5b的核苷抑制剂、其制备方法及用途 - Google Patents

2-{[(2r,3s,5r)-5-(4-氨基-2-氧代-2h-嘧啶-1-基)-3-羟基-四氢-呋喃-2-基甲氧基]-苯氧基-磷酰基氨基}-丙酸烷基酯类、hcv rna-聚合酶ns5b的核苷抑制剂、其制备方法及用途 Download PDF

Info

Publication number
CN105263941A
CN105263941A CN201480024794.3A CN201480024794A CN105263941A CN 105263941 A CN105263941 A CN 105263941A CN 201480024794 A CN201480024794 A CN 201480024794A CN 105263941 A CN105263941 A CN 105263941A
Authority
CN
China
Prior art keywords
furan
tetrahydro
oxo
pyrimidin
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480024794.3A
Other languages
English (en)
Chinese (zh)
Inventor
亚历山大·瓦西里耶维奇·伊瓦切恩科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asavi Co ltd
Original Assignee
Asavi Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asavi Co ltd filed Critical Asavi Co ltd
Publication of CN105263941A publication Critical patent/CN105263941A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480024794.3A 2013-03-22 2014-02-19 2-{[(2r,3s,5r)-5-(4-氨基-2-氧代-2h-嘧啶-1-基)-3-羟基-四氢-呋喃-2-基甲氧基]-苯氧基-磷酰基氨基}-丙酸烷基酯类、hcv rna-聚合酶ns5b的核苷抑制剂、其制备方法及用途 Pending CN105263941A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013112744/04A RU2534613C2 (ru) 2013-03-22 2013-03-22 Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
RU2013112744 2013-03-22
PCT/RU2014/000104 WO2014148949A1 (ru) 2013-03-22 2014-02-19 Алкил 2-{[(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)-3-гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино}-пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения

Publications (1)

Publication Number Publication Date
CN105263941A true CN105263941A (zh) 2016-01-20

Family

ID=51580483

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480024794.3A Pending CN105263941A (zh) 2013-03-22 2014-02-19 2-{[(2r,3s,5r)-5-(4-氨基-2-氧代-2h-嘧啶-1-基)-3-羟基-四氢-呋喃-2-基甲氧基]-苯氧基-磷酰基氨基}-丙酸烷基酯类、hcv rna-聚合酶ns5b的核苷抑制剂、其制备方法及用途

Country Status (10)

Country Link
US (1) US20160031927A1 (https=)
EP (1) EP2977379A1 (https=)
JP (1) JP2016515545A (https=)
KR (1) KR20150132879A (https=)
CN (1) CN105263941A (https=)
AU (1) AU2014238517A1 (https=)
CA (1) CA2907455A1 (https=)
EA (1) EA025878B1 (https=)
RU (1) RU2534613C2 (https=)
WO (1) WO2014148949A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108732280A (zh) * 2017-04-18 2018-11-02 广东东阳光药业有限公司 一种分离检测盐酸达卡他韦及其光学异构体的方法
CN109843900A (zh) * 2016-08-19 2019-06-04 桑多斯股份公司 治疗丙型肝炎的索非布韦衍生物
CN111233955A (zh) * 2020-02-28 2020-06-05 南京缘聚医药科技有限公司 一类噻唑酮甲酰胞嘧啶衍生物及其药物用途
CN111902419A (zh) * 2018-01-24 2020-11-06 St制药株式会社 新的核苷或核苷酸衍生物及其用途
CN116751241A (zh) * 2022-08-12 2023-09-15 杭州爱科瑞思生物医药有限公司 2’-去氧-2’,2’-二氟胞苷ProTide的制备及其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015061683A1 (en) * 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
RU2016125213A (ru) 2013-11-27 2017-12-29 АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Нуклеотиды для лечения рака печени
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
CN104546783A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种索非布韦薄膜包衣片制剂及其制备方法
CN106132972B (zh) * 2015-02-06 2018-08-31 银杏树药业(苏州)有限公司 用于治疗hcv感染的氨基磷酸酯
CN106310269B (zh) * 2015-07-03 2021-01-29 中国药科大学 一种具有抗丙型肝炎病毒作用的药物组合物
WO2017070355A1 (en) * 2015-10-20 2017-04-27 Emory University Response-guided hcv therapy
RU2606951C1 (ru) * 2015-11-19 2017-01-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Дихлорацетаты замещенных N4-[2-(диметилфосфорил)фенил]-N2-(2-метокси-4-пиперидин-1-илфенил)-5-хлорпиримидин-2,4-диаминов в качестве модуляторов ALK и EGFR, предназначенных для лечения рака
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN110045108B (zh) * 2019-05-28 2021-10-29 江南大学 一种基于辣椒碱指标的地沟油酶联免疫检测试剂盒及其检测方法
KR102145025B1 (ko) * 2020-02-20 2020-08-14 에스티팜 주식회사 신규한 뉴클레오사이드 또는 뉴클레오타이드 유도체 및 이들의 용도

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339752A (ja) 1986-08-02 1988-02-20 Kawada Tekko Kk インデツクス装置
KR100719606B1 (ko) 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
BR9913406A (pt) 1998-09-04 2002-01-29 Viropharma Inc Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
KR20010079907A (ko) 1998-09-25 2001-08-22 비로파마 인코포레이티드 바이러스 감염 및 관련 질병의 치료 및 예방 방법
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
DE60034027T2 (de) 1999-12-24 2007-12-13 Asahi Glass Co., Ltd. Siliziumnitridfilter und verfahren zu dessen herstellung
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
EP1964569A3 (en) 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
KR100798579B1 (ko) 2001-03-31 2008-01-28 동화약품공업주식회사 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
CN101624391A (zh) 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス(ケイマン)リミテツド 4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
WO2003037262A2 (en) 2001-10-29 2003-05-08 Smithkline Beecham Corporation Novel anit-infectives
WO2003099801A1 (en) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
WO2003105770A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
BR0312271A (pt) 2002-06-28 2007-11-06 Idenix Cayman Ltd compostos, composições e seus usos para o tratamento de infecções por flaviviridae
MXPA04012779A (es) 2002-06-28 2005-08-19 Idenix Cayman Ltd Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
AU2003256619A1 (en) 2002-07-24 2004-02-09 Isis Pharmaceuticals, Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
EP2361913A1 (en) 2002-11-01 2011-08-31 Abbott Laboratories Anti-infective agents
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
AU2003300957A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
AU2003300956A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
EP1630136B1 (en) 2003-03-31 2012-07-11 Toto Ltd. Surface-modified titanium dioxide fine particles and dispersion comprising the same, and method for producing the same
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2012142075A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN102775458B (zh) * 2011-05-09 2015-11-25 中国人民解放军军事医学科学院毒物药物研究所 β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843900A (zh) * 2016-08-19 2019-06-04 桑多斯股份公司 治疗丙型肝炎的索非布韦衍生物
CN108732280A (zh) * 2017-04-18 2018-11-02 广东东阳光药业有限公司 一种分离检测盐酸达卡他韦及其光学异构体的方法
CN111902419A (zh) * 2018-01-24 2020-11-06 St制药株式会社 新的核苷或核苷酸衍生物及其用途
CN111902419B (zh) * 2018-01-24 2023-11-24 St制药株式会社 新的核苷或核苷酸衍生物及其用途
CN111233955A (zh) * 2020-02-28 2020-06-05 南京缘聚医药科技有限公司 一类噻唑酮甲酰胞嘧啶衍生物及其药物用途
CN111233955B (zh) * 2020-02-28 2022-06-10 南京缘聚医药科技有限公司 一类噻唑酮甲酰胞嘧啶衍生物及其药物用途
CN116751241A (zh) * 2022-08-12 2023-09-15 杭州爱科瑞思生物医药有限公司 2’-去氧-2’,2’-二氟胞苷ProTide的制备及其应用

Also Published As

Publication number Publication date
RU2013112744A (ru) 2014-09-27
AU2014238517A1 (en) 2015-11-12
EA025878B1 (ru) 2017-02-28
CA2907455A1 (en) 2014-09-25
KR20150132879A (ko) 2015-11-26
RU2534613C2 (ru) 2014-11-27
WO2014148949A1 (ru) 2014-09-25
US20160031927A1 (en) 2016-02-04
EA201401063A1 (ru) 2015-01-30
JP2016515545A (ja) 2016-05-30
EP2977379A1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
RU2534613C2 (ru) Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
JP5982007B2 (ja) Hcvrna複製の阻害薬としての2’,4’−ジフルオロ−2’−メチル置換されたヌクレオシド誘導体
EP2808325B1 (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
US8889701B1 (en) Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
US8709999B2 (en) Substituted bicyclic HCV inhibitors
CN104011060A (zh) 作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物
JP2016519146A (ja) 4’−アジド,3’−デオキシ−3’−フルオロ置換ヌクレオシド誘導体
RU2567854C1 (ru) Нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
RU2553996C1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
CN105073734A (zh) 用于治疗病毒疾病的[(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-甲氧羰基氨基-3-甲基-丁酰基)-吡咯烷-2-基]-3h-咪唑-4-基}-丁-1,3-二炔基)-苯基]-1h-咪唑-2-基}-吡咯烷-1-羰基)-2-甲基-丙基]-氨基甲酸烷基酯萘-1,5-二磺酸盐
HK1199036B (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160120